SAN DIEGO , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the Cowen 41st Annual Health Care Conference which takes place March 1-4, 2021 . Ron Rocca , Exagen’s President and Chief Executive Officer, and Kamal

SAN DIEGO , Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), a leading autoimmune organization, today announced its participation in the BTIG MedTech, Digital Health , Life Science & Diagnostic Tools Conference , which takes place February 17-19, 2021 .

SAN DIEGO , Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX,

Record Testing Revenue, Adopters and AVISE CTD ® Volumes SAN DIEGO , Jan. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported preliminary, unaudited financial results for

SAN DIEGO , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that company management will participate in the 2021 ICR Conference , which takes place January

SAN DIEGO , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc.  (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that all AVISE test offerings (CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX,